| Ytd | 27.82% | |
| 1y | 1.18% |
| Open | 12.62 | Prev Close | 12.59 | Low | 12.46 | High | 13.12 | Mkt Cap | 445.67M |
| Vol | 373.64K | Avg Vol | 463.15K | EPS | 0.01 | P/E | 1291.00 | Forward P/E | -35.75 |
| Beta | 0.76 | Short Ratio | 5.26 | Inst. Own | 38.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 11.30 | 200-d Avg | 10.29 | 1yr Est | 21.33 |
DCTH News
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.03) per share which beat the analyst
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on liver-directed ca
BTIG analyst Marie Thibault maintains Delcath Systems (NASDAQ:DCTH) with a Buy and lowers the pri
Delcath Systems (NASDAQ:DCTH) FY2026 Total CHEMOSAT and HEPZATO KIT Revenue expected to be more than
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.05) per share which beat the analyst
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) w
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional
Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath") an interventional oncology company focused
Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional
Stephens & Co. analyst Sudan Loganathan maintains Delcath Systems (NASDAQ:DCTH) with a Overwe
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.02 per share which beat the analyst
Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and main
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Preliminary Third Quarter Financial Results (unaudited)Total CHEMOSAT and HEPZATO KIT revenue of app
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Delcath Systems (NASDAQ:DCTH) reported quarterly earnings of $0.07 per share which beat the analyst
Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overw
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Delcath Systems (NASDAQ:DCTH) wi
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.11) per share which missed the analys
Craig-Hallum analyst Chase Knickerbocker maintains Delcath Systems (NASDAQ:DCTH) with a Buy and r
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) w
Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 M
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) w
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.06) per share which beat the analyst
Canaccord Genuity analyst John Newman maintains Delcath Systems (NASDAQ:DCTH) with a Buy and main
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) w
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, t
Key Findings from the Study:Overall Survival (OS): The study reported median OS of 22.4 months for p